ATLANTA, March 19, 2018 (GLOBE NEWSWIRE) -- Cardlytics, Inc., (NASDAQ:CDLX), a purchase intelligence platform that
helps make marketing more relevant and measurable, today announced financial results for the fourth quarter and full year ended
December 31, 2017.
“We are pleased to report solid fourth quarter and full year 2017 financial results, with annual 25% growth in Cardlytics Direct
revenue. We are excited to begin a new chapter as a publicly traded company, and our 2017 performance reflects continued strong
execution across the board, including increasing FI MAUs and expanding our base of advertisers and verticals,” said Scott Grimes,
CEO & Co-Founder of Cardlytics. “Looking to 2018 and beyond, we are excited about the opportunities ahead of us for continued
expansion of our purchase intelligence platform.”
Fourth Quarter 2017 Financial Results
- Total revenue was $39.3 million compared to $36.4 million in the fourth quarter of 2016.
- Cardlytics Direct revenue was $38.8 million, an increase of 22% compared to $31.8 million in the fourth quarter
2016.
- GAAP net loss was $(4.1) million compared to a loss of $(7.0) million in the fourth quarter of 2016.
- GAAP net loss attributable to common stockholders was $(4.4) million, or $(1.26) per share based on 3.50 million
weighted-average common shares outstanding, compared to a loss of $(7.3) million, or $(2.82) per share based on 2.58 million
weighted-average common shares outstanding in the fourth quarter of 2016.
- Adjusted contribution, a non-GAAP metric, was $16.9 million compared to $15.1 million in the fourth quarter of 2016.
- Adjusted EBITDA, a non-GAAP metric, was $0.5 million compared to a loss of $(0.2) million in the fourth quarter of
2016.
- Non-GAAP net loss was $(2.6) million, or $(0.18) per share based on 14.14 million non-GAAP weighted-average common shares
outstanding, compared to a loss of $(4.7) million, or $(0.41) per share based on 11.58 million non-GAAP weighted-average common
shares outstanding in the fourth quarter of 2016.
Full Year 2017 Financial Results
- Total revenue was $130.4 million compared to $112.8 million in 2016.
- Cardlytics Direct revenue was $122.4 million, an increase of 25% compared to $97.8 million in 2016.
- GAAP net loss was $(19.6) million, compared to a net loss of $(75.7) million in 2016.
- GAAP net loss attributable to common stockholders was $(25.4) million, or $(7.86) per share based on 3.23 million
weighted-average common shares outstanding, compared to a net loss of $(76.7) million, or $(32.48) per share based on 2.36
million weighted-average common shares outstanding in 2016.
- Adjusted contribution, a non-GAAP metric, was $57.1 million compared to $46.5 million in 2016.
- Adjusted EBITDA, a non-GAAP metric, was a loss of $(7.2) million compared to a loss of $(17.0) million in 2016.
- Non-GAAP net loss was $(20.1) million, or $(1.51) per share based on 13.32 million non-GAAP weighted-average common shares
outstanding, compared to a loss of $(29.1) million, or $(2.52) per share based on 11.57 million non-GAAP weighted-average common
shares outstanding in 2016.
- Cardlytics ended 2017 with $21.3 million in cash and cash equivalents, compared with $22.8 million at the end of 2016.
Subsequent to December 31, 2017, Cardlytics closed its initial public offering on February 8, 2018, which generated net proceeds
to Cardlytics of $66.1 million.
“We ended 2017 on a high note, delivering strong fourth quarter financial results. We are excited to enter 2018 as a public
company and look forward to ongoing collaboration with our FI partners and continued traction among our advertisers,” said David
Evans, CFO of Cardlytics.
Key Metrics
- FI MAUs were 54.9 million in 2017, an increase of 25% compared to 43.9 million in 2016. FI MAUs were 58.7 million in the
fourth quarter of 2017, an increase of 24% compared to 47.5 million in the fourth quarter of 2016.
- ARPU was $2.23 in both 2017 and 2016. ARPU was $0.66 in the fourth quarter of 2017 compared to $0.67 in the fourth quarter of
2016.
* Definitions of FI MAUs and ARPU are included below under the caption “Use of Non-GAAP Financial
Measures.”
2018 Financial Expectations (in millions)
Cardlytics anticipates revenue and non-GAAP adjusted EBITDA to be in the following ranges:
|
|
|
|
|
Q1
2018 |
|
Full year 2018 |
|
|
|
|
Revenue |
$29.5 - 30.0 |
|
$157 - 160 |
Non-GAAP adjusted EBITDA** |
$(4.9) - (4.7) |
|
$(12.6) - (11.4) |
Estimated weighted average shares |
17.5 |
|
19.8 |
|
|
|
|
** With respect to our expectations above under the caption “2018 Financial Expectations,” a reconciliation of adjusted EBITDA
to net loss on a forward looking basis is not available without unreasonable efforts due to the high variability, complexity
and low visibility with respect to the items excluded from this non-GAAP measure. We have provided a reconciliation of
historical non-GAAP financial measures to the most comparable GAAP measures in the financial statement tables included in this
press release. Adjusted EBITDA as presented above excludes the impact of any charges related to FI Share commitments as well
as non-cash charges related to the issuance of equity instruments to our FI partners, which we expect to total $2.5 million in the
first quarter of 2018, and otherwise reflects the definition of adjusted EBITDA as set forth under the caption “Use of Non-GAAP
Financial Measures.”
Earnings Teleconference Information
Cardlytics will discuss its fourth quarter and full year 2017 financial results during a teleconference today, March 19, 2018, at
5:00 PM ET / 2:00 PM PT. The conference call can be accessed at (866) 385-4179 (domestic) or (210) 874-7775 (international),
conference ID# 6078757. A replay of the conference call will be available through 8:00 PM ET / 5:00 PM PT on March 26, 2018 at
(855) 859-2056 (domestic) or (404) 537-3406 (international). The replay passcode is 6078757. The call will also be broadcast
simultaneously at http://ir.cardlytics.com/. Following the completion of the call, a recorded replay of the
webcast will be available on Cardlytics’ website.
About Cardlytics
Cardlytics (NASDAQ:CDLX) uses purchase intelligence to make marketing more relevant and measurable. We partner with more than 2,000
financial institutions to run their banking rewards programs that promote customer loyalty and deepen banking relationships. In
turn, we have a secure view into where and when consumers are spending their money. We use these insights to help marketers
identify, reach, and influence likely buyers at scale, as well as measure the true sales impact of marketing campaigns.
Headquartered in Atlanta, Cardlytics has offices in London, New York, Chicago and San Francisco. Learn more at
www.cardlytics.com.
Cautionary Language Concerning Forward-Looking Statements:
This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995, including but not limited to our financial guidance for the first quarter of 2018 and
full year 2018. These forward-looking statements are made as of the date they were first issued and were based on current
expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as "expect,"
"anticipate," "should," "believe," "hope," "target," "project," "goals," "estimate," "potential," "predict," "may," "will,"
"might," "could," "intend," variations of these terms or the negative of these terms and similar expressions are intended to
identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of
which involve factors or circumstances that are beyond our control. Our actual results could differ materially from those
stated or implied in forward-looking statements due to a number of factors, including but not limited to: our financial
performance, including our revenues, margins, costs, expenditures, growth rates and operating expenses, and our ability to sustain
revenue growth, generate positive cash flow and become profitable; risks related to our substantial dependence on its Cardlytics
Direct product; risks related to our substantial dependence on Bank of America, N.A. and a limited number of other financial
institution partners; the amount and timing of budgets by advertisers, which are affected by budget cycles, economic conditions and
other factors; our ability to generate sufficient revenue to offset contractual commitments to FIs; our ability to attract new FI
partners and maintain relationships with bank processors and digital banking providers; our ability to maintain relationships with
marketers; our ability to adapt to changing market conditions, including our ability to adapt to changes in consumer habits,
negotiate fee arrangements with new and existing financial institutions and retailers, and develop and launch new services and
features; our significant amount of debt, which may affect our ability to operate the business and secure additional financing in
the future, and other risks detailed in the “Risk Factors” section of our prospectus filed pursuant to Rule 424(b)(4) under the
Securities Act of 1933 on February 9, 2018 and in subsequent periodic reports that we file with the Securities and Exchange
Commission. Past performance is not necessarily indicative of future results. The forward-looking statements included in this
press release represent our views as of the date of this press release. We anticipate that subsequent events and developments
will cause our views to change. We undertake no intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise, except as required by law. These forward-looking
statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Use of Non-GAAP Financial Measures
To supplement the financial measures presented in our press release and related conference call or webcast in accordance with
generally accepted accounting principles in the United States ("GAAP"), we also present the following non-GAAP measures of
financial performance: adjusted contribution, adjusted EBITDA, non-GAAP net loss and non-GAAP loss per share.
A “non-GAAP financial measure” refers to a numerical measure of our historical or future financial performance or financial
position that is included in (or excluded from) the most directly comparable measure calculated and presented in accordance with
GAAP in our financial statements. We provide certain non-GAAP measures as additional information relating to our operating results
as a complement to results provided in accordance with GAAP. The non-GAAP financial information presented herein should be
considered in conjunction with, and not as a substitute for or superior to, the financial information presented in accordance with
GAAP and should not be considered a measure of liquidity. There are significant limitations associated with the use of non-GAAP
financial measures. Further, these measures may differ from the non-GAAP information, even where similarly titled, used by other
companies and therefore should not be used to compare our performance to that of other companies.
We have presented adjusted contribution, adjusted EBITDA, non-GAAP net loss and non-GAAP net loss per share as non-GAAP
financial measures in this press release. We define adjusted contribution as our revenue less our FI Share and other
third-party costs. We define adjusted EBITDA as our net loss before income tax benefit; interest expense, net; depreciation
and amortization; stock-based compensation expense; change in fair value of warrant liability; change in fair value of convertible
promissory notes; foreign currency (gain) loss; loss on extinguishment of debt; costs associated with financing events;
restructuring costs; amortization and impairment of deferred FI implementation costs; and termination of U.K. agreement expense. We
define non-GAAP net loss as our net loss before stock-based compensation expense; change in fair value of warrant liability; change
in fair value of convertible promissory notes; foreign currency (gain) loss; loss on extinguishment of debt; costs associated with
financing events; restructuring costs; and termination of U.K. agreement expense. We define non-GAAP net loss per share as non-GAAP
net loss divided by non-GAAP weighted-average common shares outstanding, basic and diluted, which includes our GAAP
weighted-average common shares outstanding, basic and diluted, and our weighted-average preferred shares outstanding, assuming
conversion.
We believe the use of non-GAAP financial measures, as a supplement to GAAP measures, is useful to investors in that they
eliminate items that are either not part of our core operations or do not require a cash outlay, such as stock-based compensation.
Management uses these non-GAAP financial measures when evaluating operating performance and for internal planning and forecasting
purposes. We believe that these non-GAAP financial measures help indicate underlying trends in the business, are important in
comparing current results with prior period results, and are useful to investors and financial analysts in assessing operating
performance.
* We define FI monthly active users (“FI MAUs”), as unique customers of our financial institution (“FI”) partners that logged in
and visited the online or mobile banking applications of, or opened an email from, our FI partners during a monthly period. We then
calculate a monthly average of FI MAUs for the periods presented above. We define average revenue per user (“ARPU”), as the total
GAAP Cardlytics Direct revenue generated in the applicable period, divided by the average number of FI MAUs in the applicable
period.
|
|
|
|
|
CARDLYTICS, INC. |
CONSOLIDATED BALANCE SHEETS |
(Amounts in thousands) |
|
|
|
|
|
|
|
Year Ended |
|
|
December 31, |
|
|
2017 |
|
2016 |
ASSETS |
|
|
|
|
CURRENT ASSETS: |
|
|
|
|
Cash and cash equivalents |
|
$ |
21,262 |
|
|
$ |
22,838 |
|
Restricted cash |
|
|
- |
|
|
|
130 |
|
Accounts receivable, net |
|
|
48,348 |
|
|
|
42,042 |
|
Other receivables |
|
|
2,898 |
|
|
|
1,774 |
|
Prepaid expenses and other assets |
|
|
2,121 |
|
|
|
1,540 |
|
Total current assets |
|
|
74,629 |
|
|
|
68,324 |
|
PROPERTY AND EQUIPMENT, net |
|
|
7,319 |
|
|
|
8,345 |
|
INTANGIBLE ASSETS, net |
|
|
528 |
|
|
|
476 |
|
CAPITALIZED SOFTWARE DEVELOPMENT COSTS, net |
|
|
433 |
|
|
|
- |
|
DEFERRED FI IMPLEMENTATION COSTS, net |
|
|
13,625 |
|
|
|
8,451 |
|
OTHER LONG-TERM ASSETS |
|
|
4,224 |
|
|
|
1,263 |
|
Total assets |
|
$ |
100,758 |
|
|
$ |
86,859 |
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDER'S DEFICIT |
|
|
|
|
CURRENT LIABILITIES: |
|
|
|
|
Accounts payable |
|
|
1,554 |
|
|
|
2,369 |
|
Accrued liabilities: |
|
|
|
|
Accrued compensation |
|
|
4,638 |
|
|
|
3,122 |
|
Accrued expenses |
|
|
4,615 |
|
|
|
4,410 |
|
FI Share liability |
|
|
23,914 |
|
|
|
23,109 |
|
Consumer Incentive liability |
|
|
7,242 |
|
|
|
5,857 |
|
Deferred billings |
|
|
132 |
|
|
|
638 |
|
Short-term debt: |
|
|
|
|
Capital leases |
|
|
44 |
|
|
|
99 |
|
Total current liabilities |
|
$ |
42,139 |
|
|
$ |
39,604 |
|
|
|
|
|
|
LONG-TERM LIABILITIES: |
|
|
|
|
Deferred liabilities |
|
|
3,670 |
|
|
|
4,071 |
|
Warrant liability |
|
|
10,230 |
|
|
|
2,197 |
|
Long-term debt, net of current portion: |
|
|
|
|
Lines of credit |
|
|
25,081 |
|
|
|
15,652 |
|
Term loans |
|
|
31,830 |
|
|
|
23,715 |
|
Capital leases |
|
|
57 |
|
|
|
101 |
|
Convertible promissory notes (recognized at fair value through net
loss) |
|
|
- |
|
|
|
8,662 |
|
Convertible promissory notes—related parties (recognized
at fair value through net loss) |
|
- |
|
|
|
63,670 |
|
Total long-term liabilities |
|
$ |
70,868 |
|
|
$ |
118,068 |
|
|
|
|
|
|
Total redeemable convertible preferred stock |
|
$ |
196,437 |
|
|
$ |
146,022 |
|
|
|
|
|
|
STOCKHOLDER'S DEFICIT: |
|
|
|
|
Common stock |
|
|
- |
|
|
|
- |
|
Additional paid-in capital |
|
|
58,693 |
|
|
|
29,867 |
|
Accumulated other comprehensive income |
|
|
1,066 |
|
|
|
2,102 |
|
Accumulated deficit |
|
|
(268,445 |
) |
|
|
(248,804 |
) |
Total stockholders' deficit |
|
|
(208,686 |
) |
|
|
(216,835 |
) |
Total liabilities and stockholders' deficit |
|
$ |
100,758 |
|
|
$ |
86,859 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CARDLYTICS, INC. |
CONSOLIDATED STATEMENTS OF
OPERATIONS |
(Amounts in thousands except per share
amounts) |
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Year Ended |
|
December 31, |
|
December 31, |
|
2017 |
|
2016 |
|
2017 |
|
2016 |
|
|
|
|
|
|
|
|
REVENUE |
$ |
39,266 |
|
|
$ |
36,421 |
|
|
$ |
130,365 |
|
|
$ |
112,821 |
|
COSTS AND EXPENSES: |
|
|
|
|
|
|
|
FI Share and other third-party costs |
|
22,361 |
|
|
|
21,299 |
|
|
|
73,247 |
|
|
|
66,285 |
|
Delivery costs |
|
1,917 |
|
|
|
1,398 |
|
|
|
7,012 |
|
|
|
6,127 |
|
Sales and marketing expense |
|
8,473 |
|
|
|
8,411 |
|
|
|
31,927 |
|
|
|
31,261 |
|
Research and development expense |
|
2,623 |
|
|
|
2,801 |
|
|
|
12,150 |
|
|
|
13,902 |
|
General and administrative expense |
|
5,362 |
|
|
|
5,115 |
|
|
|
20,100 |
|
|
|
21,355 |
|
Depreciation and amortization expense |
|
725 |
|
|
|
787 |
|
|
|
3,028 |
|
|
|
4,219 |
|
Termination of U.K. agreement expense |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
25,904 |
|
Total costs and expenses |
|
41,461 |
|
|
|
39,811 |
|
|
|
147,464 |
|
|
|
169,053 |
|
OPERATING LOSS |
|
(2,195 |
) |
|
|
(3,390 |
) |
|
|
(17,099 |
) |
|
|
(56,232 |
) |
|
|
|
|
|
|
|
|
OTHER INCOME (EXPENSE): |
|
|
|
|
|
|
|
Interest expense, net |
|
(1,812 |
) |
|
|
(2,547 |
) |
|
|
(8,239 |
) |
|
|
(6,170 |
) |
Change in fair value of warrant liability |
|
(169 |
) |
|
|
(671 |
) |
|
|
(581 |
) |
|
|
(32 |
) |
Change in fair value of convertible promissory notes |
|
- |
|
|
|
32 |
|
|
|
(1,244 |
) |
|
|
(786 |
) |
Change in fair value of convertible promissory notes—related
parties |
|
- |
|
|
|
190 |
|
|
|
6,213 |
|
|
|
(10,091 |
) |
Other income (expense), net |
|
120 |
|
|
|
(659 |
) |
|
|
1,309 |
|
|
|
(2,385 |
) |
Total other expense |
|
(1,861 |
) |
|
|
(3,655 |
) |
|
|
(2,542 |
) |
|
|
(19,464 |
) |
LOSS BEFORE INCOME TAXES |
|
(4,056 |
) |
|
|
(7,045 |
) |
|
|
(19,641 |
) |
|
|
(75,696 |
) |
INCOME TAX BENEFIT |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
NET LOSS |
$ |
(4,056 |
) |
|
$ |
(7,045 |
) |
|
$ |
(19,641 |
) |
|
$ |
(75,696 |
) |
Adjustments to the carrying value of redeemable convertible
preferred stock |
|
(360 |
) |
|
|
(241 |
) |
|
|
(5,743 |
) |
|
|
(982 |
) |
Net loss attributable to common stockholders |
$ |
(4,416 |
) |
|
$ |
(7,286 |
) |
|
$ |
(25,384 |
) |
|
$ |
(76,678 |
) |
Net loss per share attributable to common stockholders, basic and diluted |
$ |
(1.26 |
) |
|
$ |
(2.82 |
) |
|
$ |
(7.86 |
) |
|
$ |
(32.48 |
) |
Weighted-average common shares outstanding, basic and diluted |
|
3,498 |
|
|
|
2,582 |
|
|
|
3,230 |
|
|
|
2,361 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CARDLYTICS, INC. |
STOCK-BASED COMPENSATION
EXPENSE |
(Amounts in thousands) |
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Year Ended |
|
December 31, |
|
December 31, |
|
2017 |
|
2016 |
|
2017 |
|
2016 |
|
|
|
|
|
|
|
|
Delivery costs |
$ |
56 |
|
$ |
28 |
|
$ |
202 |
|
$ |
96 |
Sales and marketing expense |
|
504 |
|
|
327 |
|
|
1,894 |
|
|
1,153 |
Research and development expense |
|
260 |
|
|
155 |
|
|
951 |
|
|
574 |
General and administrative expense |
|
620 |
|
|
696 |
|
|
2,100 |
|
|
1,624 |
Total stock-based compensation expense |
$ |
1,440 |
|
$ |
1,206 |
|
$ |
5,147 |
|
$ |
3,447 |
|
|
|
|
|
|
|
|
|
|
|
|
|
CARDLYTICS, INC. |
CONSOLIDATED STATEMENTS OF CASH
FLOWS |
(Amounts in thousands) |
|
|
|
|
|
|
|
Year Ended |
|
|
December 31, |
|
|
2017 |
|
2016 |
CASH FLOWS FROM OPERATING ACTIVITIES: |
|
|
|
|
Net loss |
|
$ |
(19,641 |
) |
|
$ |
(75,696 |
) |
|
|
|
|
|
Adjustments to reconcile net loss to net cash used in operating
activities: |
|
|
|
|
Increase in allowance for doubtful accounts |
|
|
73 |
|
|
|
1,100 |
|
Depreciation and amortization expense |
|
|
3,028 |
|
|
|
4,219 |
|
Amortization of financing costs charged to interest expense |
|
|
560 |
|
|
|
297 |
|
Accretion of debt discount charged to interest expense |
|
|
6,889 |
|
|
|
4,368 |
|
Stock-based compensation expense |
|
|
5,147 |
|
|
|
3,447 |
|
Termination of U.K. agreement expense |
|
|
- |
|
|
|
25,904 |
|
Change in fair value warrant liability |
|
|
581 |
|
|
|
32 |
|
Change in fair value of convertible promissory notes |
|
|
1,244 |
|
|
|
786 |
|
Change in fair value of convertible promissory notes—related
parties |
|
|
(6,213 |
) |
|
|
10,091 |
|
Other non-cash expenses |
|
|
451 |
|
|
|
6,809 |
|
Change in operating assets and liabilities: |
|
|
|
|
Accounts receivable |
|
|
(7,503 |
) |
|
|
(5,789 |
) |
Prepaid expenses and other assets |
|
|
(666 |
) |
|
|
(529 |
) |
Deferred FI implementation costs |
|
|
(6,800 |
) |
|
|
(8,200 |
) |
Accounts payable |
|
|
(1,907 |
) |
|
|
(1,234 |
) |
Other accrued expenses |
|
|
466 |
|
|
|
(3,940 |
) |
Payable to related party, net |
|
|
- |
|
|
|
(459 |
) |
FI Share liability |
|
|
804 |
|
|
|
8,482 |
|
Consumer incentive liability |
|
|
1,385 |
|
|
|
(2,186 |
) |
Total adjustment |
|
|
(2,461 |
) |
|
|
43,198 |
|
Net cash used in operating activities |
|
$ |
(22,102 |
) |
|
$ |
(32,498 |
) |
|
|
|
|
|
CASH FLOWS FROM INVESTING ACTIVITIES: |
|
|
|
|
Acquisition of property and equipment |
|
|
(1,215 |
) |
|
|
(1,827 |
) |
Acquisition of intangible assets |
|
|
(60 |
) |
|
|
(72 |
) |
Capitalized software development costs |
|
|
(372 |
) |
|
|
(646 |
) |
Net cash used in investing activities |
|
$ |
(1,647 |
) |
|
$ |
(2,545 |
) |
|
|
|
|
|
CASH FLOWS FROM FINANCING ACTIVITIES: |
|
|
|
|
Proceeds from issuance of debt |
|
|
12,500 |
|
|
|
46,794 |
|
Proceeds from issuance of debt — related parties |
|
|
- |
|
|
|
19,485 |
|
Principal payments of debt |
|
|
(99 |
) |
|
|
(32,346 |
) |
Proceeds from issuance of common stock |
|
|
230 |
|
|
|
279 |
|
Proceeds from issuance of Series G preferred stock |
|
|
11,940 |
|
|
|
- |
|
Equity issuance costs |
|
|
(2,668 |
) |
|
|
(1,674 |
) |
Debt issuance costs |
|
|
(142 |
) |
|
|
(1,417 |
) |
Debt extinguishment costs |
|
|
- |
|
|
|
(312 |
) |
Net cash from financing activities |
|
$ |
21,761 |
|
|
$ |
30,809 |
|
|
|
|
|
|
Effect of exchange rates on cash, cash equivalents and restricted cash |
|
|
282 |
|
|
|
(407 |
) |
Net decrease in cash, cash equivalents and restricted cash |
|
|
(1,706 |
) |
|
|
(4,641 |
) |
Cash, cash equivalents and restricted cash - beginning of period |
|
|
22,968 |
|
|
|
27,609 |
|
Cash, cash equivalents and restricted cash - end of period |
|
$ |
21,262 |
|
|
$ |
22,968 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CARDLYTICS, INC. |
RECONCILIATION OF GAAP REVENUE TO NON-GAAP
ADJUSTED CONTRIBUTION |
(Amounts in thousands) |
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Year Ended |
|
December 31, |
|
December 31, |
|
2017 |
|
2016 |
|
2017 |
|
2016 |
Revenue |
$ |
39,266 |
|
$ |
36,421 |
|
$ |
130,365 |
|
$ |
112,821 |
Minus: |
|
|
|
|
|
|
|
FI Share and other third-party costs |
|
22,361 |
|
|
21,299 |
|
|
73,247 |
|
|
66,285 |
Adjusted contribution |
$ |
16,905 |
|
$ |
15,122 |
|
$ |
57,118 |
|
$ |
46,536 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CARDLYTICS, INC. |
RECONCILIATION OF GAAP NET LOSS TO NON-GAAP
ADJUSTED EBITDA |
(Amounts in thousands) |
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Year Ended |
|
December 31, |
|
December 31, |
|
2017 |
|
2016 |
|
2017 |
|
2016 |
Net loss |
$ |
(4,056 |
) |
|
$ |
(7,045 |
) |
|
$ |
(19,641 |
) |
|
$ |
(75,696 |
) |
Plus: |
|
|
|
|
|
|
|
Income tax benefit |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Interest expense, net |
|
1,812 |
|
|
|
2,547 |
|
|
|
8,239 |
|
|
|
6,170 |
|
Depreciation and amortization |
|
725 |
|
|
|
787 |
|
|
|
3,028 |
|
|
|
4,219 |
|
Stock-based compensation expense |
|
1,440 |
|
|
|
1,206 |
|
|
|
5,147 |
|
|
|
3,447 |
|
Change in fair value of warrant liability |
|
169 |
|
|
|
671 |
|
|
|
581 |
|
|
|
32 |
|
Change in fair value of convertible promissory notes |
|
- |
|
|
|
(222 |
) |
|
|
(4,969 |
) |
|
|
10,877 |
|
Foreign currency (gain) loss |
|
(119 |
) |
|
|
656 |
|
|
|
(1,318 |
) |
|
|
1,926 |
|
Loss on extinguishment of debt |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
462 |
|
Costs associated with financing events |
|
- |
|
|
|
- |
|
|
|
129 |
|
|
|
2,632 |
|
Restructuring costs |
|
- |
|
|
|
7 |
|
|
|
- |
|
|
|
1,291 |
|
Amortization and impairment of deferred FI implementation costs |
|
516 |
|
|
|
1,191 |
|
|
|
1,626 |
|
|
|
1,690 |
|
Termination of UK agreement expense |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
25,904 |
|
Adjusted EBITDA |
$ |
487 |
|
|
$ |
(202 |
) |
|
$ |
(7,178 |
) |
|
$ |
(17,046 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CARDLYTICS, INC. |
RECONCILIATION OF GAAP NET LOSS TO NON-GAAP
NET LOSS |
(Amounts in thousands except per share
amounts) |
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Year Ended |
|
December 31, |
|
December 31, |
|
2017 |
|
2016 |
|
2017 |
|
2016 |
Net loss |
$ |
(4,056 |
) |
|
$ |
(7,045 |
) |
|
$ |
(19,641 |
) |
|
$ |
(75,696 |
) |
Plus: |
|
|
|
|
|
|
|
Change in fair value of warrant liability |
|
169 |
|
|
|
671 |
|
|
|
581 |
|
|
|
32 |
|
Change in fair value of convertible promissory notes |
|
- |
|
|
|
(222 |
) |
|
|
(4,969 |
) |
|
|
10,877 |
|
Foreign currency (gain) loss |
|
(119 |
) |
|
|
656 |
|
|
|
(1,318 |
) |
|
|
1,926 |
|
Stock-based compensation expense |
|
1,440 |
|
|
|
1,206 |
|
|
|
5,147 |
|
|
|
3,447 |
|
Loss on extinguishment of debt |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
462 |
|
Costs associated with financing events |
|
- |
|
|
|
- |
|
|
|
129 |
|
|
|
2,632 |
|
Restructuring costs |
|
- |
|
|
|
7 |
|
|
|
- |
|
|
|
1,291 |
|
Termination of UK agreement expense |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
25,904 |
|
Non-GAAP net loss |
$ |
(2,566 |
) |
|
$ |
(4,727 |
) |
|
$ |
(20,071 |
) |
|
$ |
(29,125 |
) |
|
|
|
|
|
|
|
|
Weighted-average number of shares of common stock used in computing non-GAAP net
loss per share: |
|
|
|
|
|
|
|
GAAP weighted-average common shares outstanding, basic and
diluted |
|
3,498 |
|
|
|
2,582 |
|
|
|
3,230 |
|
|
|
2,361 |
|
Weighted-average preferred shares, assuming conversion |
|
10,643 |
|
|
|
9,001 |
|
|
|
10,090 |
|
|
|
9,205 |
|
Non-GAAP weighted-average common shares outstanding, basic and
diluted |
|
14,141 |
|
|
|
11,583 |
|
|
|
13,320 |
|
|
|
11,566 |
|
|
|
|
|
|
|
|
|
Non-GAAP net loss per share attributable to common stockholders, basic and
diluted |
$ |
(0.18 |
) |
|
$ |
(0.41 |
) |
|
$ |
(1.51 |
) |
|
$ |
(2.52 |
) |
|
|
|
|
|
|
|
|
Contacts:
Public Relations:
ICR
cardlyticspr@icrinc.com
Investor Relations:
Denise Garcia and William Maina
ICR, Inc.
(646) 277-1236
ir@cardlytics.com